Kiniksa製藥上調2026年Arcalyst產品淨收入指引至9.3-9.45億美元

美股速遞

04/28

Kiniksa Pharmaceuticals Ltd. (KNSA) 宣佈調整其2026財年的財務預期，將核心產品Arcalyst的淨收入指引區間提升至9.3億至9.45億美元。這一修正反映出公司對該藥物市場表現和未來增長潛力的強勁信心。

此次指引上調基於Arcalyst在自身炎症性疾病治療領域的持續商業化成功以及不斷擴大的市場接納度。公司管理層指出，該調整也考慮了當前積極的處方趨勢和預期的市場需求增長。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1137071546"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137071546\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137071546?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-04-28 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137071546","market":"us","top_or_hot":-1,"title":"Kiniksa製藥上調2026年Arcalyst產品淨收入指引至9.3-9.45億美元","media":"美股速遞","content":"<p>Kiniksa Pharmaceuticals Ltd. (KNSA) 宣佈調整其2026財年的財務預期，將核心產品Arcalyst的淨收入指引區間提升至9.3億至9.45億美元。這一修正反映出公司對該藥物市場表現和未來增長潛力的強勁信心。</p>\n<p>此次指引上調基於Arcalyst在自身炎症性疾病治療領域的持續商業化成功以及不斷擴大的市場接納度。公司管理層指出，該調整也考慮了當前積極的處方趨勢和預期的市場需求增長。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kiniksa製藥上調2026年Arcalyst產品淨收入指引至9.3-9.45億美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKiniksa製藥上調2026年Arcalyst產品淨收入指引至9.3-9.45億美元\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速遞 </p>\n<p class=\"h-time smaller\">2026-04-28 19:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Kiniksa Pharmaceuticals Ltd. (KNSA) 宣佈調整其2026財年的財務預期，將核心產品Arcalyst的淨收入指引區間提升至9.3億至9.45億美元。這一修正反映出公司對該藥物市場表現和未來增長潛力的強勁信心。</p>\n<p>此次指引上調基於Arcalyst在自身炎症性疾病治療領域的持續商業化成功以及不斷擴大的市場接納度。公司管理層指出，該調整也考慮了當前積極的處方趨勢和預期的市場需求增長。</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴資本持倉","start_time":0,"source_url":"","article_id":"1137071546","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137071546","pubTimestamp":1777375977,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速遞","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Kiniksa Pharmaceuticals Ltd. (KNSA) 宣佈調整其2026財年的財務預期，將核心產品Arcalyst的淨收入指引區間提升至9.3億至9.45億美元。這一修正反映出公司對該藥物市場表現和未來增長潛力的強勁信心。\n此次指引上調基於Arcalyst在自身炎症性疾病治療領域的持續商業化成功以及不斷擴大的市場接納度。公司管理層指出，該調整也考慮了當前積極的處方趨勢和預期的市場需求增長。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4505":"高瓴资本持仓","KNSA":"Kiniksa Pharmaceuticals Ltd.","BK4139":"生物科技"},"translate_title":"Kiniksa Pharmaceuticals raises 2026 Arcalyst product net revenue guidance to $930-$945 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNSA":1},"content_text":"Kiniksa Pharmaceuticals Ltd. (KNSA) 宣佈調整其2026財年的財務預期，將核心產品Arcalyst的淨收入指引區間提升至9.3億至9.45億美元。這一修正反映出公司對該藥物市場表現和未來增長潛力的強勁信心。\n此次指引上調基於Arcalyst在自身炎症性疾病治療領域的持續商業化成功以及不斷擴大的市場接納度。公司管理層指出，該調整也考慮了當前積極的處方趨勢和預期的市場需求增長。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}